FDA-approved device label expansion enabled by Truveta

Expanding the labeled indications of an approved medical device often requires generating new prospective clinical trial evidence, a process that can take years for small, clinically complex patient populations. Increasingly, real-world evidence is providing a faster, more efficient path to answering these questions.

This case study demonstrates how Truveta supported an FDA-approved label expansion for a surgically implanted medical device. By emulating a single-arm clinical study using longitudinal, device-level real-world data, the sponsor generated the evidence needed to support a Premarket Approval (PMA) supplement submission—cutting evidence generation timelines in half while reducing study costs compared with traditional approaches.